Ranbaxy settles issue with US health regulator – New Kerala

According to the company, Ranbaxy will market cravit (levofloxacin), a synthetic antibacterial agent to treat various infections in Malaysia from Jan 1, 2012. The product is currently marketed by Malaysia-based First Pharma.

Leave a Reply

Your email address will not be published.

*